Klee Justin B. 4

What Happened
Justin B. Klee, CEO of Amylyx Pharmaceuticals (AMLX), sold 15,500 shares on Feb 2, 2026 in an open-market/private sale for a total of approximately $227,618. The reported weighted-average price was $14.69 per share (individual trade prices ranged $14.51–$14.76). The filing indicates the shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units — an automatic, non-discretionary sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Transaction type/code: Sale (S).
• Shares sold: 15,500; weighted-average price: $14.69; total value: $227,618.
• Footnote F1: Sale required to cover tax withholding on vested RSUs; automatic, not at the insider’s discretion.
• Footnote F2: Price is a weighted average; trades ranged $14.51–$14.76. Full per-trade breakdown available to the SEC on request.
• Shares owned after the transaction: not provided in the excerpted transaction details.
• Filing does not indicate a 10b5-1 plan or other trading plan.

Context
Sales to cover tax withholding on vested restricted stock units are common and generally considered routine administrative transactions rather than directional insider bets. This transaction should be interpreted as fulfilling tax obligations on compensation vesting, not necessarily as a signal about the CEO’s view of the company’s stock.